Avocadoflex® in the development of health supplement products supporting people with osteoarthritis

1. General introduction to Avocadoflex®

• Avocadoflex® is a plant-derived ingredient belonging to the Avocado-Soybean Unsaponifiables (ASU) group. It consists of the unsaponifiable fractions extracted from avocado fruit and soybean seeds, corresponding to the botanical species Persea americana and Glycine max, respectively.
• According to a scientific study published in 2026, Avocadoflex® is a standardized ASU preparation containing at least 30% total phytosterols. This specification is based on the combined content of three major phytosterols: beta-sitosterol, campesterol, and stigmasterol.
• ASU has been investigated in the field of osteoarthritis due to its potential effects on inflammatory processes and cartilage extracellular matrix metabolism. These processes are associated with structural and functional changes in the joints of individuals with osteoarthritis.
• So, what is Avocadoflex® and how can it be applied in product development? With its standardized phytosterol content and research data directly evaluating the ingredient, Avocadoflex® is a noteworthy option for R&D teams exploring ingredients for cartilage and joint health and developing health supplements targeting individuals with osteoarthritis.

2. Mechanism of action and functional properties of Avocadoflex®

The research value of Avocadoflex® focuses on its potential effects on several biological processes associated with cartilage degeneration, including inflammatory responses, extracellular matrix-degrading enzyme activity, and markers related to cartilage matrix synthesis.

A study published in the journal Nutrients in 2026 directly evaluated Avocadoflex® in a monosodium iodoacetate (MIA)-induced osteoarthritis model in Sprague-Dawley rats. The findings provided preclinical data on the ingredient's effects across several indicators associated with joint damage.

2.1. Modulation of factors associated with inflammatory responses

• In osteoarthritis, pro-inflammatory cytokines such as Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α) participate in regulating inflammatory responses within joint tissues. Increased levels of these factors are associated with changes in chondrocyte activity and the joint microenvironment.
• In the MIA-induced osteoarthritis rat model, Avocadoflex® was reported to reduce serum levels of IL-6, TNF-α, and Prostaglandin E2 (PGE2) in the group receiving the medium dose. The study also reported changes in the gene expression of several inflammatory mediators in cartilage tissue.
• These findings suggest that Avocadoflex® may influence certain inflammatory markers in an experimental model. However, these results are based on animal data and are insufficient to establish an anti-inflammatory effect in humans with osteoarthritis.

2.2. Effects on cartilage extracellular matrix-degrading enzymes

• The extracellular matrix is an essential component for maintaining the structure and mechanical properties of articular cartilage. During osteoarthritis progression, increased activity of matrix-degrading enzymes may contribute to cartilage deterioration.
• Matrix Metalloproteinases (MMPs) are a group of enzymes involved in the degradation of extracellular matrix components. Among them, MMP-3 can degrade various matrix components and participate in the activation of other enzymes. MMP-13 plays an important role in the degradation of type II collagen in cartilage.
• The 2026 study reported that Avocadoflex® reduced serum levels of several MMPs, including MMP-1, MMP-2, MMP-9, and MMP-13. The research team also observed reduced expression of certain genes associated with matrix degradation in cartilage tissue.
• These findings indicate that the ingredient may influence certain markers associated with cartilage matrix degradation in an animal model. However, changes in MMP concentrations do not necessarily demonstrate that the ingredient can prevent osteoarthritis progression in humans.

2.3. Effects on markers associated with cartilage matrix synthesis

• In addition to matrix degradation, maintaining extracellular matrix synthesis is another important factor in preserving articular cartilage structure.
• Type II collagen is the primary structural component of articular cartilage. SOX9 is a transcription factor involved in regulating chondrocyte differentiation and the expression of cartilage matrix-related genes. Meanwhile, TIMP-1 (Tissue Inhibitor of Metalloproteinases-1) helps regulate MMP activity.
• In the MIA-induced osteoarthritis model, the group receiving the medium dose of Avocadoflex® showed increased expression of the Col2a1, Sox9, and Timp1 genes in cartilage tissue. At the same time, Col1a1 expression decreased compared with the disease control group.
• These results reflect changes in gene expression associated with cartilage matrix metabolism. They provide additional grounds for investigating Avocadoflex® as an ingredient for supporting cartilage structure maintenance, but do not constitute direct evidence of articular cartilage regeneration.
• Evidence limitations: In the 2026 study, Avocadoflex® was administered for two weeks before osteoarthritis induction and continued for another four weeks afterward. Therefore, the findings primarily reflect protective effects in an experimental model. These results cannot be used to establish therapeutic efficacy in individuals who already have osteoarthritis.

3. Applications of Avocadoflex® in health supplement formulation development

Based on research data on ASU and direct preclinical findings for Avocadoflex®, this ingredient has potential applications in joint health supplements. For R&D teams, selecting the appropriate dosage form and developing a formulation should be based on the ingredient's actual properties, phytosterol content, and grade-specific stability data.

3.1. Development of hard capsule products

• Capsules are a dosage form documented in the commercial application of Avocadoflex®. One example is Joint Protect & Repair by Harker Herbals, a product that combines Avocadoflex® with other botanical ingredients in a capsule formulation.
• According to the ingredient information published on the brand's official website, each capsule contains 100 mg of Avocadoflex®, providing at least 30 mg of phytosterols. The formulation also includes Boswellia, Fermeric®, and Gotu Kola.
• For R&D teams, this is a reference example of using Avocadoflex® in a multi-ingredient capsule product. When developing a similar formulation, the following factors should be evaluated:
• Phytosterol content: Verify the total phytosterol specification and batch-to-batch consistency of the raw material.
• Raw material characteristics: Evaluate moisture content, powder properties, and physical specifications based on the supplier's technical documentation.
• Capsule filling performance: Assess flow properties, ingredient distribution, and content uniformity during capsule filling.
• Stability: Evaluate potential changes in Avocadoflex® quality under storage conditions and within the finished formulation.
• Ingredient compatibility: Assess compatibility with the selected active ingredients and excipients.
• Solubility, flowability, and storage conditions should not be assumed without appropriate TDS, COA, and supporting experimental data.

3.2. Research and development of multi-ingredient formulations

• For products targeting individuals with osteoarthritis, R&D teams may investigate Avocadoflex® in combination with other ingredients to establish a more clearly defined product concept.
• Several ingredient groups commonly investigated in joint health products include glucosamine, chondroitin sulfate, undenatured type II collagen, and MSM. However, each ingredient has its own characteristics and supporting research. Their combination with Avocadoflex® should be evaluated based on the formulation objectives and available evidence supporting the individual ingredients and the overall combination.

Key formulation considerations include:

• The intended role of each ingredient in the formulation.
• Total active ingredient content and the capacity of the selected dosage form to accommodate the required amounts.
• Compatibility between ingredients under storage conditions.
• Content uniformity and finished product stability.
• Scientific evidence supporting each ingredient and the combination, where available.
• A combination of multiple joint health ingredients should not automatically be assumed to produce a synergistic effect. The efficacy of the complete formulation must be evaluated using appropriate supporting data.

3.3. Evaluation of clinical evidence for ASU in osteoarthritis

• In addition to preclinical data, the ASU ingredient group has been investigated in clinical trials involving individuals with knee and hip osteoarthritis.
• A meta-analysis by Simental-Mendía et al., published in 2019, evaluated randomized, placebo-controlled trials investigating the efficacy and safety of ASU. The results indicated that ASU was associated with improvements in Visual Analogue Scale (VAS) pain scores among patients with knee osteoarthritis. However, subgroup analysis by joint location did not demonstrate a similar statistically significant benefit in patients with hip osteoarthritis. The authors also reported substantial heterogeneity across some studies.
• A Cochrane review by Cameron and Chrubasik also concluded that ASU may provide slight improvements in pain and physical function in individuals with osteoarthritis. However, the available evidence did not demonstrate a clear benefit in preserving joint space based on X-ray imaging.
• Key consideration for R&D: The clinical studies evaluated ASU preparations as a group and should not automatically be considered clinical trials directly investigating Avocadoflex®. Therefore, it is important to distinguish clinical evidence for ASU in general from ingredient-specific data for Avocadoflex®. The 2026 study provides direct preclinical evidence for Avocadoflex®, but current findings are insufficient to establish its clinical efficacy in humans with osteoarthritis.

4. Representative commercial product containing Avocadoflex®

One commercial product containing Avocadoflex® that has been verified through the ingredient information published on the official Harker Herbals website is Joint Protect & Repair.

Product category	Brand and product	Application of Avocadoflex® in the product
	Harker Herbals – Joint Protect & Repair	Provides ASU-derived nutrients intended to work alongside other botanical ingredients to support joint cartilage protection.